Richard Schilsky to Cisplatin
This is a "connection" page, showing publications Richard Schilsky has written about Cisplatin.
Connection Strength
0.782
-
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). Clin Cancer Res. 1997 May; 3(5):719-25.
Score: 0.126
-
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol. 1994 Dec; 12(12):2743-50.
Score: 0.107
-
Biochemical pharmacology of chemotherapeutic drugs used as radiation enhancers. Semin Oncol. 1992 Aug; 19(4 Suppl 11):2-7.
Score: 0.091
-
Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol. 1990 Dec; 8(12):2054-61.
Score: 0.081
-
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer. Cancer Res. 1986 Aug; 46(8):4184-8.
Score: 0.060
-
Cytarabine-cis-platin interactions in patients with advanced cancer. Semin Oncol. 1985 Jun; 12(2 Suppl 3):171-6.
Score: 0.055
-
Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep. 1982 Sep; 66(9):1767-9.
Score: 0.046
-
Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 1979 Jun; 90(6):929-31.
Score: 0.036
-
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol. 1996 Jun; 14(6):1964-5.
Score: 0.030
-
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients. Eur J Cancer. 1991; 27(2):217-8.
Score: 0.020
-
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1990 Feb; 8(2):241-7.
Score: 0.019
-
Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing. Cancer. 1989 Mar 15; 63(6 Suppl):1018-21.
Score: 0.018
-
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005 Apr 01; 23(10):2191-200.
Score: 0.014
-
Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer. Cancer Treat Rep. 1984 Sep; 68(9):1097-102.
Score: 0.013
-
Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol. 1982 Mar; 9(1):75-83.
Score: 0.011
-
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1979 Sep-Oct; 63(9-10):1527-31.
Score: 0.009
-
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. J Clin Oncol. 1998 Oct; 16(10):3302-9.
Score: 0.009
-
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol. 1997; 39(3):227-32.
Score: 0.008
-
Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B. Cancer. 1991 Oct 15; 68(8):1696-8.
Score: 0.005
-
Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B. Med Pediatr Oncol. 1990; 18(3):197-202.
Score: 0.005
-
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. Cancer. 1989 Mar 15; 63(6 Suppl):1048-53.
Score: 0.004
-
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer. 1989 Jan 01; 63(1):30-6.
Score: 0.004
-
Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol. 1988 Apr; 6(4):618-26.
Score: 0.004
-
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer. NCI Monogr. 1988; (6):353-6.
Score: 0.004
-
Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined Modality Trial. Cancer Treat Rep. 1979 Sep-Oct; 63(9-10):1687-92.
Score: 0.002